MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.035
-0.015
-0.73%
Opening 13:08 06/22 EDT
OPEN
2.050
PREV CLOSE
2.050
HIGH
2.070
LOW
1.990
VOLUME
445.16K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
1.870
MARKET CAP
150.69M
P/E (TTM)
-1.6715
1D
5D
1M
3M
1Y
5Y
BRIEF-Final Data From Calithera Biosciences’ Phase 2 Cantata Study In Renal Cell Carcinoma Presented At 2021 Asco Annual Meeting
reuters.com · 06/07 12:46
Final Data from Calithera Biosciences' Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared final results from the Phase 2...
GlobeNewswire · 06/07 12:11
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/01 20:32
Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-thr...
GlobeNewswire · 05/27 11:00
Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings
Benzinga · 05/17 14:08
BRIEF-Calithera Biosciences And Antengene Enter Worldwide License Agreement For Development & Commercialization Of Cb-708
reuters.com · 05/17 12:55
Calithera Biosciences and Antengene ink worldwide exclusive license agreement
Calithera Biosciences (CALA) and Antengene announce an exclusive, worldwide license agreement for the development and commercialization of CB-708 (ATG-037).CB-708 is Calithera's small molecule inhibitor of CD73, which generates adenosine that is highly
Seekingalpha · 05/17 12:29
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708; Calithera Will Receive An Upfront Payment Of $255M
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, and
Benzinga · 05/17 12:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CALA. Analyze the recent business situations of Calithera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CALA stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 157
Institutional Holdings: 61.23M
% Owned: 82.69%
Shares Outstanding: 74.05M
TypeInstitutionsShares
Increased
34
3.80M
New
18
3.35M
Decreased
33
2.73M
Sold Out
19
5.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.48%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Susan Molineaux
Chief Financial Officer/Secretary/IR Contact Officer
Stephanie Wong
Senior Vice President/Chief Compliance Officer/General Counsel
Sumita Ray
Senior Vice President
Christopher Molineaux
Senior Vice President
Francesco Parlati
Senior Vice President
Eric Sjogren
Other
Keith Orford
Lead Director/Independent Director
Deepa Pakianathan
Lead Director/Independent Director
Deepika Pakianathan
Independent Director
Sunil Agarwal
Independent Director
Jonathan Drachman
Independent Director
Scott Garland
Independent Director
Jean George
Independent Director
Suzy Jones
Independent Director
Blake Wise
Independent Director
H. Ward Wolff
No Data
About CALA
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.